Development of many critically important pharmaceuticals, existing and yet to come, grows out of macromolecular x-ray crystallography (MX)-based research carried out at sources of high-brightness x-rays such as the U.S. Department of Energy Office of Science’s Advanced Photon Source (APS) at Argonne National Laboratory, and at the proposed APS Upgrade that will open new vistas in drug discovery.